Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasma propranolol steady state concentrations in thyroid disorders

J Feely, J Crooks, I H Stevenson

    European Journal of Clinical Pharmacology
    |January 1, 1981
    PubMed
    Summary

    Thyroid disorders significantly alter propranolol levels in the body. Hyperthyroidism increases propranolol concentrations, while hypothyroidism decreases them, affecting drug efficacy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Drugs in Hospital.

    Journal of the Royal College of Physicians of London·2019
    Same author

    A positive Monospot test in a diabetic with sarcoidosis.

    Irish journal of medical science·2016
    Same author

    The application of the fast, multi-hit, pixel imaging mass spectrometry sensor to spatial imaging mass spectrometry.

    The Review of scientific instruments·2012
    Same author

    The effect of fluphenazine on steady state plasma levels of nortriptyline.

    British journal of clinical pharmacology·2012
    Same author

    A survey of patients' attitudes to clinical research.

    Irish medical journal·2011
    Same author

    Prevalence of dyslipidaemia in statin-treated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS).

    Irish journal of medical science·2011

    Area of Science:

    • Pharmacology
    • Endocrinology
    • Clinical Pharmacy

    Background:

    • Thyroid disorders, such as hyperthyroidism and hypothyroidism, are known to affect drug metabolism and disposition.
    • Propranolol, a beta-blocker, is commonly used but its pharmacokinetics may be influenced by thyroid status.

    Purpose of the Study:

    • To investigate the impact of thyroid disorders on plasma propranolol steady-state concentrations (Css).
    • To evaluate changes in propranolol handling following correction of hyperthyroidism and hypothyroidism.

    Main Methods:

    • Measurement of plasma propranolol Css in hyperthyroid and hypothyroid patients before and after treatment.
    • Analysis of changes in area under the plasma propranolol concentration-time curve (AUC) and plasma protein binding.

    Main Results:

    • Following hyperthyroid treatment, plasma propranolol Css significantly increased, with a notable rise in AUC.
    • In hypothyroid patients, plasma propranolol Css significantly decreased after becoming euthyroid.
    • Thyroid disorder correction led to significant changes in propranolol plasma protein binding.

    Conclusions:

    • Thyroid dysfunction markedly influences propranolol pharmacokinetics.
    • Dosage adjustments for propranolol may be necessary in patients with thyroid disorders.
    • Understanding these interactions is crucial for optimizing propranolol therapy.

    Related Experiment Videos